Literature DB >> 27411421

A case of hyperkinetic movement disorder associated with LGI1 antibodies.

Sevda Erer Özbek1, Zuhal Yapıcı, Erdem Tüzün, Murat Giriş, Selcen Duran, Özlem Taşkapılıoğlu, Mehmet Okan.   

Abstract

Encephalitis associated with leucine-rich glioma inactivated 1 (LGI1) antibodies is often encountered in elderly male patients and may infrequently present with isolated syndromes. A 6-year-old boy was admitted with acute onset severe oral and facial stereotypic and choreiform movements. On his neurologic examination, he had repetitive and rhythmic movements in orolingual muscles including tongue protrusion, limb chorea and minimal facial stereotypic movements. Anti-streptolysin O (ASO) titers were found severely elevated in several measurements. Well-characterized antibodies against ion channels and synapse proteins were negative whereas LGI1 antibody was positive in both serum and CSF. Marked clinical improvement was observed after immunotherapy. Here, we present the first pediatric case with LGI1 antibody associated hyperkinetic movement disorders and emphasize the importance of investigating neuronal autoantibodies in patients with isolated and treatment resistant movement disorders.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 27411421

Source DB:  PubMed          Journal:  Turk J Pediatr        ISSN: 0041-4301            Impact factor:   0.552


  2 in total

1.  Case Report: Isolated Epileptic Seizures Associated With Anti-LGI1 Antibodies in a 7-Year-Old Girl With Literature Review.

Authors:  Ying Wang; Wei-Hua Zhang; Yuan Wang
Journal:  Front Pediatr       Date:  2022-05-31       Impact factor: 3.569

2.  Glial fibrillary acidic protein (GFAP)-antibody in children with focal seizures of undetermined cause.

Authors:  Merve Savaş; John Tzartos; Cem İsmail Küçükali; Erdinç Dursun; Katerina Karagiorgou; Duygu Gezen-Ak; Dilşad Türkdoğan; Aliki Papaconstantinou; Sezin Başoğlu; Nilüfer Hacıhafızoğlu; Büşra Kutlubay; Socrates Tzartos; Erdem Tüzün
Journal:  Acta Neurol Belg       Date:  2020-04-24       Impact factor: 2.396

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.